|
|
|
原研机构- |
在研适应症- |
|
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期- |
Open-label Randomized Crossover Two Period Single Dose Bioequivalence Study of Two Formulations of Perindopril (Perindopril Tert-butylamine) 8 mg (Pharmtechnology LLC, Republic of Belarus) and Prestarium® A 10 mg (Perindopril Arginine) 10 mg Tablets (Les Laboratoires Servier Industrie, France) in Healthy Volunteers Under Fasting Conditions
This is an open-labeled, randomized, two period, single-center, crossover, comparative study, where each participant will be randomly assigned to the reference (Prestarium ® A 10 mg tablets) or the test (Perindopril 8 mg tablets) formulation in each period of study (sequences Test-Reference (TR) or Reference-Test (RT)), in order to evaluate if both formulations are bioequivalent.
Open-label Randomized Crossover Two Period Single Dose Bioequivalence Study of Two Formulations of Perindopril Erbumine/Indapamide/Amlodipine 8 mg/2.5 mg/10 mg Tablets (Pharmtechnology LLC, Republic of Belarus) and Triplixam® 10 mg/2.5 mg/10 mg Tablets (Les Laboratoires Servier Industrie, France) in Healthy Volunteers Under Fasting Conditions
This is an open-labeled, randomized, two period, single-center, crossover, comparative study, where each participant will be randomly assigned to the reference (Triplixam®, 10 mg/2.5 mg/10 mg tablets) or the test (Perindopril Erbumine/ 8 mg/2.5 mg/10 mg Tablets) formulation in each period of study (sequences Test-Reference (TR) or Reference-Test (RT)), in order to evaluate if both formulations are bioequivalent.
An Open-label, Blinded, Randomized Crossover Four Period Single Dose Full Replicative Bioequivalence Study of Two Formulations Clopidogrel Film-coated Tablets 75 mg (Pharmtechnology LLC, Republic of Belarus) and Plavix® Film-coated Tablets 75 mg (Manufacturer: Sanofi Winthrop Industry, France; Holder RU: Sanofi-Aventis Group S.A., France) in Healthy Volunteers Under Fasting Conditions.
This is an open-labeled, randomized, four period, single-center, crossover, full replicative, comparative study, where each participant will be randomly assigned to the reference (Plavix®, 75 mg film-coated tablets) or the test (Clopidogrel, 75 mg film-coated tablets) formulation in each period of study (sequences Test-Reference (TR) or Reference-Test (RT)), in order to evaluate if both formulations are bioequivalent.
100 项与 Pharmtechnology, LLC 相关的临床结果
0 项与 Pharmtechnology, LLC 相关的专利(医药)
100 项与 Pharmtechnology, LLC 相关的药物交易
100 项与 Pharmtechnology, LLC 相关的转化医学